Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Alzheimer's Disease

Free Subscription Articles published in Brain Retrieve available abstracts of 230 articles: HTML format

Single Articles

May 2024
1. CHEN F, Zhao J, Meng F, He F, et al
   The vascular contribution of apolipoprotein E to Alzheimer's disease.
   Brain. 2024 May 15:awae156. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. SOCH J, Richter A, Kizilirmak JM, Schutze H, et al
   Single-value brain activity scores reflect both severity and risk across the Alzheimer's continuum.
   Brain. 2024 May 14:awae149. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. BLUM D, Levi S
   Targeting excitatory:inhibitory network imbalance in Alzheimer's disease.
   Brain. 2024 May 13:awae146. doi: 10.1093.
   PubMed    
   
   
   
4. SANCHEZ-JUAN P, Valeriano-Lorenzo E, Ruiz-Gonzalez A, Pastor AB, et al
   Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles.
   Brain. 2024;147:1667-1679.
   PubMed     Abstract available
   
   
   
5. DING F, Sun Q, Long C, Rasmussen RN, et al
   Dysregulation of extracellular potassium distinguishes healthy ageing from neurodegeneration.
   Brain. 2024;147:1726-1739.
   PubMed     Abstract available
   
   
   April 2024
6. CODY KA, Langhough RE, Zammit MD, Clark L, et al
   Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
   Brain. 2024 Apr 26:awae116. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. BARBOUR AJ, Gourmaud S, Lancaster E, Li X, et al
   Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer's disease and 5XFAD mice.
   Brain. 2024 Apr 25:awae126. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. LIMBERGER C, Zimmer ER
   Blood GFAP reflects astrocyte reactivity to Alzheimer's pathology in post-mortem brain tissue.
   Brain. 2024 Apr 18:awae104. doi: 10.1093.
   PubMed    
   
   
   
9. 
   Correction to: Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia.
   Brain. 2024 Apr 10:awae103. doi: 10.1093.
   PubMed    
   
   
   
10. WANG YT, Therriault J, Servaes S, Tissot C, et al
    Sex-specific modulation of amyloid-beta on tau phosphorylation underlies faster tangle accumulation in females.
    Brain. 2024;147:1497-1510.
    PubMed     Abstract available
    
    
    
11. TANAKA H, Martinez-Valbuena I, Forrest SL, Couto B, et al
    Distinct involvement of the cranial and spinal nerves in progressive supranuclear palsy.
    Brain. 2024;147:1399-1411.
    PubMed     Abstract available
    
    
    
12. CORRIVEAU-LECAVALIER N, Barnard LR, Botha H, Graff-Radford J, et al
    Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases.
    Brain. 2024;147:1483-1496.
    PubMed     Abstract available
    
    
    March 2024
13. HUNG C, Fertan E, Livesey FJ, Klenerman D, et al
    APP antisense oligonucleotides reduce Abeta aggregation and rescue endolysosomal dysfunction in Alzheimer's disease.
    Brain. 2024 Mar 25:awae092. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. RODRIGUEZ-RODRIGUEZ P, Arroyo-Garcia LE, Tsagkogianni C, Li L, et al
    A cell autonomous regulator of neuronal excitability modulates tau in Alzheimer's disease vulnerable neurons.
    Brain. 2024 Mar 11:awae051. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. RODRIGUEZ-VIEITEZ E, Vannini P, Montal V, Graff C, et al
    Cortical microstructural imaging from diffusion MRI: towards sensitive biomarkers for clinical trials.
    Brain. 2024;147:746-748.
    PubMed    
    
    
    
16. DE MEYER S, Blujdea ER, Schaeverbeke J, Reinartz M, et al
    Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
    Brain. 2024;147:936-948.
    PubMed     Abstract available
    
    
    February 2024
17. YANG HS, Yau WW, Carlyle BC, Trombetta BA, et al
    Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
    Brain. 2024 Feb 5:awae034. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. AHMED H, Wang Y, Griffiths WJ, Levey AI, et al
    Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development.
    Brain. 2024 Feb 1:awae028. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. ALBERT-GASCO H, Smith HL, Alvarez-Castelao B, Swinden D, et al
    Trazodone rescues dysregulated synaptic and mitochondrial nascent proteomes in prion neurodegeneration.
    Brain. 2024;147:649-664.
    PubMed     Abstract available
    
    
    January 2024
20. KUMAR M, Quittot N, Dujardin S, Schlaffner CN, et al
    Alzheimer proteopathic tau seeds are biochemically a forme fruste of mature paired helical filaments.
    Brain. 2024 Jan 18:awad378. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. KIIANITSA K, Lukes ME, Hayes BJ, Brutman J, et al
    TREM2 variants that cause early dementia and increase Alzheimer's disease risk affect gene splicing.
    Brain. 2024 Jan 16:awae014. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. HAN Y, Chen K, Zhang B, Yu H, et al
    Maf1 loss regulates spinogenesis and attenuates cognitive impairment in Alzheimer's disease.
    Brain. 2024 Jan 16:awae015. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. QIN C, Chen M, Dong MH, Yang S, et al
    Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
    Brain. 2024;147:163-176.
    PubMed     Abstract available
    
    
    December 2023
24. SAMANTA S, Akhter F, Roy A, Chen D, et al
    New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease.
    Brain. 2023 Dec 26:awad432. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. SPOTORNO N, Strandberg O, Stomrud E, Janelidze S, et al
    Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer's disease.
    Brain. 2023 Dec 21:awad428. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. STOUFFER KM, Grande X, Duezel E, Johansson M, et al
    Amidst an amygdala renaissance in Alzheimer's disease.
    Brain. 2023 Dec 18:awad411. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. YUYAMA K, Sun H, Fujii R, Hemmi I, et al
    Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis.
    Brain. 2023 Dec 10:awad361. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. TARUTANI A, Kametani F, Tahira M, Saito Y, et al
    Distinct tau folds initiate templated seeding and alter the post-translational modification profile.
    Brain. 2023;146:4988-4999.
    PubMed     Abstract available
    
    
    
29. GUBERT C, Hannan AJ
    Microbial manipulation of memories and minds.
    Brain. 2023;146:4791-4793.
    PubMed    
    
    
    November 2023
30. QUESNEL MJ, Labonte A, Picard C, Zetterberg H, et al
    Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains.
    Brain. 2023 Nov 22:awad398. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. SILVA-RODRIGUEZ J, Labrador-Espinosa MA, Moscoso A, Scholl M, et al
    Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
    Brain. 2023;146:4520-4531.
    PubMed     Abstract available
    
    
    
32. HAMPEL H, Elhage A, Cho M, Apostolova LG, et al
    Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
    Brain. 2023;146:4414-4424.
    PubMed     Abstract available
    
    
    
33. RAMANAN VK, Gebre RK, Graff-Radford J, Hofrenning E, et al
    Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis.
    Brain. 2023;146:4508-4519.
    PubMed     Abstract available
    
    
    October 2023
34. GRABRUCKER S, Marizzoni M, Silajdzic E, Lopizzo N, et al
    Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis.
    Brain. 2023 Oct 18:awad303. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. TUNOLD JA, Tan MMX, Koga S, Geut H, et al
    Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease.
    Brain. 2023;146:4077-4087.
    PubMed     Abstract available
    
    
    
36. KEPP KP, Robakis NK, Hoilund-Carlsen PF, Sensi SL, et al
    The amyloid cascade hypothesis: an updated critical review.
    Brain. 2023;146:3969-3990.
    PubMed     Abstract available
    
    
    
37. DU F, Yu Q, Swerdlow RH, Waites CL, et al
    Glucocorticoid-driven mitochondrial damage stimulates Tau pathology.
    Brain. 2023;146:4378-4394.
    PubMed     Abstract available
    
    
    September 2023
38. COOMANS EM, van Westen D, Pichet Binette A, Strandberg O, et al
    Interactions between vascular burden and amyloid-beta pathology on trajectories of tau accumulation.
    Brain. 2023 Sep 18:awad317. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. HARDY J, Mummery C
    Reply: Lecanemab: turning point, or status quo? An ethics perspective.
    Brain. 2023;146:e73.
    PubMed    
    
    
    
40. BOCANCEA DI, Svenningsson AL, van Loenhoud AC, Groot C, et al
    Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.
    Brain. 2023;146:3719-3734.
    PubMed     Abstract available
    
    
    
41. DALY T
    Lecanemab: turning point, or status quo? An ethics perspective.
    Brain. 2023;146:e71-e72.
    PubMed    
    
    
    
42. COOMANS EM, Tomassen J, Ossenkoppele R, Tijms BM, et al
    Genetically identical twin-pair difference models support the amyloid cascade hypothesis.
    Brain. 2023;146:3735-3746.
    PubMed     Abstract available
    
    
    August 2023
43. KERAMIDIS I, McAllister BB, Bourbonnais J, Wang F, et al
    Restoring neuronal chloride extrusion reverses cognitive decline linked to Alzheimer's disease mutations.
    Brain. 2023 Aug 8:awad250. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. JUNG Y, Damoiseaux JS
    The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease.
    Brain. 2023 Aug 4:awad267. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. WUESTEFELD A, Pichet Binette A, Berron D, Spotorno N, et al
    Age-related and amyloid-beta-independent tau deposition and its downstream effects.
    Brain. 2023;146:3192-3205.
    PubMed     Abstract available
    
    
    
46. RAHAYEL S, Tremblay C, Vo A, Misic B, et al
    Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies.
    Brain. 2023;146:3301-3318.
    PubMed     Abstract available
    
    
    
47. MCMILLAN PJ, Benbow SJ, Uhrich R, Saxton A, et al
    Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.
    Brain. 2023;146:3206-3220.
    PubMed     Abstract available
    
    
    July 2023
48. GARCIA AM, de Leon J, Tee BL, Blasi DE, et al
    Speech and language markers of neurodegeneration: a call for global equity.
    Brain. 2023 Jul 27:awad253. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. AKSMAN LM, Oxtoby NP, Scelsi MA, Wijeratne PA, et al
    A data-driven study of Alzheimer's disease related amyloid and tau pathology progression.
    Brain. 2023 Jul 11:awad232. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. YOUNG AL, Vogel JW, Robinson JL, McMillan CT, et al
    Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.
    Brain. 2023;146:2975-2988.
    PubMed     Abstract available
    
    
    June 2023
51. 
    Correction to: Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
    Brain. 2023 Jun 27:awad208. doi: 10.1093.
    PubMed    
    
    
    
52. VAN DER ENDE EL, In 't Veld SGJG, Hanskamp I, van der Lee S, et al
    CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease.
    Brain. 2023 Jun 22:awad213. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. BANERJEE G, Collinge J, Fox NC, Lashley T, et al
    Clinical considerations in early-onset cerebral amyloid angiopathy.
    Brain. 2023 Jun 6:awad193. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. SCHOONHOVEN DN, Coomans EM, Millan AP, van Nifterick AM, et al
    Tau protein spreads through functionally connected neurons in Alzheimer's disease: a combined MEG/PET study.
    Brain. 2023 Jun 5:awad189. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. 
    Correction: The most valuable player or the tombstone: is tau the correct target to treat Alzheimer's disease?
    Brain. 2023 Jun 1:awad176. doi: 10.1093.
    PubMed    
    
    
    
56. EDWARDS HM, Wallace CE, Gardiner WD, Doherty BM, et al
    Sex-dependent effects of acute stress on amyloid-beta in male and female mice.
    Brain. 2023;146:2268-2274.
    PubMed     Abstract available
    
    
    
57. ROBINSON JL, Xie SX, Baer DR, Suh E, et al
    Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated.
    Brain. 2023;146:2557-2569.
    PubMed     Abstract available
    
    
    May 2023
58. ZHU M, Xiao B, Xue T, Qin S, et al
    Cdc42GAP deficiency contributes to the Alzheimer's disease phenotype.
    Brain. 2023 May 31:awad184. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. DAS V, Hajduch M
    Randomizing for Alzheimer's disease drug trials should consider the cancer history of participants.
    Brain. 2023 May 27:awad177. doi: 10.1093.
    PubMed    
    
    
    
60. HARDY J, Mummery C
    Reply: Unblinding in the lecanemab trial in Alzheimer's disease.
    Brain. 2023 May 23:awad201. doi: 10.1093.
    PubMed    
    
    
    
61. VAN GOOL WA
    Unblinding in the lecanemab trial in Alzheimer's disease.
    Brain. 2023 May 18:awad171. doi: 10.1093.
    PubMed    
    
    
    
62. KORETSKY MJ, Alvarado C, Makarious MB, Vitale D, et al
    Genetic risk factor clustering within and across neurodegenerative diseases.
    Brain. 2023 May 16:awad161. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. JIANG J, Johnson JCS, Requena-Komuro MC, Benhamou E, et al
    Comprehension of acoustically degraded speech in Alzheimer's disease and primary progressive aphasia.
    Brain. 2023 May 15:awad163. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. YOUNES K, Sha SJ
    The MVP or the tombstone: is tau the correct target to treat Alzheimer's disease?
    Brain. 2023 May 8:awad151. doi: 10.1093.
    PubMed    
    
    
    April 2023
65. GOSSYE H, Van Mossevelde S, Sieben A, Bjerke M, et al
    Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum.
    Brain. 2023;146:1624-1636.
    PubMed     Abstract available
    
    
    
66. PONNUSAMY M, Wang S, Yuksel M, Hansen MT, et al
    Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model.
    Brain. 2023;146:1561-1579.
    PubMed     Abstract available
    
    
    
67. NAM MH, Ko HY, Kim D, Lee S, et al
    Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG.
    Brain. 2023 Apr 17:awad037. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. MATTSSON-CARLGREN N, Palmqvist S
    The emerging era of staging Alzheimer's disease pathology using plasma biomarkers.
    Brain. 2023 Apr 6:awad112. doi: 10.1093.
    PubMed    
    
    
    March 2023
69. 
    Correction to: Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound.
    Brain. 2023 Mar 22:awad082. doi: 10.1093.
    PubMed    
    
    
    
70. DONADIO V, Incensi A, Rizzo G, Westermark GT, et al
    Phosphorylated alpha-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy.
    Brain. 2023;146:1065-1074.
    PubMed     Abstract available
    
    
    
71. GREVE HJ, Dunbar AL, Lombo CG, Ahmed C, et al
    The bidirectional lung brain-axis of amyloid-beta pathology: ozone dysregulates the peri-plaque microenvironment.
    Brain. 2023;146:991-1005.
    PubMed     Abstract available
    
    
    February 2023
72. HARDY J, Mummery C
    An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?
    Brain. 2023 Feb 17:awad049. doi: 10.1093.
    PubMed    
    
    
    
73. JACK CR, Wiste HJ, Algeciras-Schimnich A, Figdore DJ, et al
    Predicting amyloid PET and tau PET stages with plasma biomarkers.
    Brain. 2023 Feb 15:awad042. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. HUSAIN M
    Screening for Alzheimer's disease: plasma biomarkers and what else?
    Brain. 2023;146:407-408.
    PubMed    
    
    
    
75. FLORIAN H, Wang D, Arnold SE, Boada M, et al
    Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.
    Brain. 2023 Feb 2:awad024. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. KOCH G, Martorana A
    Reply: Can transcranial magnetic stimulation rescue dopaminergic signalling in Alzheimer disease?
    Brain. 2023 Feb 2:awad020. doi: 10.1093.
    PubMed    
    
    
    
77. D'AMELIO M, Di Lazzaro V
    Can transcranial magnetic stimulation rescue dopaminergic signalling in Alzheimer disease?
    Brain. 2023 Feb 2:awad019. doi: 10.1093.
    PubMed    
    
    
    January 2023
78. MARUSZAK A, Silajdzic E, Lee H, Murphy T, et al
    Predicting progression to Alzheimer's disease with human hippocampal progenitors exposed to serum.
    Brain. 2023 Jan 27:awac472. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. MENG Y, Goubran M, Rabin JS, McSweeney M, et al
    Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound.
    Brain. 2023 Jan 25:awac459. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. PERNECZKY R, Jessen F, Grimmer T, Levin J, et al
    Anti-amyloid antibody therapies in Alzheimer's disease.
    Brain. 2023 Jan 19:awad005. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. JOHANSSON C, Thordardottir S, Laffita-Mesa J, Rodriguez-Vieitez E, et al
    Plasma biomarker profiles in autosomal dominant Alzheimer's disease.
    Brain. 2023 Jan 11:awac399. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. WHEELOCK MD, Strain JF, Mansfield P, Tu JC, et al
    Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer's disease.
    Brain. 2023 Jan 10:awac498. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. VAN ARENDONK J, Neitzel J, Steketee RME, van Assema DME, et al
    Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study.
    Brain. 2023;146:337-348.
    PubMed     Abstract available
    
    
    
84. KATSUMI Y, Putcha D, Eckbo R, Wong B, et al
    Anterior dorsal attention network tau drives visual attention deficits in posterior cortical atrophy.
    Brain. 2023;146:295-306.
    PubMed     Abstract available
    
    
    
85. BLOMMER J, Pitcher T, Mustapic M, Eren E, et al
    Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease.
    Brain. 2023;146:195-208.
    PubMed     Abstract available
    
    
    December 2022
86. GONZALEZ-ORTIZ F, Turton M, Kac PR, Smirnov D, et al
    Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
    Brain. 2022 Dec 27:awac407. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. KOOP EA, Jacobs HIL
    Untangling white matter fibre changes in Alzheimer's disease and small vessel disease.
    Brain. 2022 Dec 26:awac493. doi: 10.1093.
    PubMed    
    
    
    
88. WISCH JK, Butt OH, Gordon BA, Schindler SE, et al
    Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression.
    Brain. 2022 Dec 21:awac484. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. PERANI D
    The impact of integrated brain molecular PET measures on DLB cognitive phenotype and clinical course.
    Brain. 2022;145:4157-4159.
    PubMed    
    
    
    November 2022
90. MOUSSAVI Z
    Repetitive TMS applied to the precuneus stabilizes cognitive status in Alzheimer's disease.
    Brain. 2022;145:3730-3732.
    PubMed    
    
    
    
91. OBERSTEIN TJ, Schmidt MA, Florvaag A, Haas AL, et al
    Amyloid-beta levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy.
    Brain. 2022;145:4032-4041.
    PubMed     Abstract available
    
    
    
92. BETTHAUSER TJ, Bilgel M, Koscik RL, Jedynak BM, et al
    Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.
    Brain. 2022;145:4065-4079.
    PubMed     Abstract available
    
    
    
93. HUGHES TM, Craft S
    Cerebral insulin receptors: a nexus for vascular and metabolic contributions to Alzheimer's disease.
    Brain. 2022 Nov 19:awac433. doi: 10.1093.
    PubMed    
    
    
    October 2022
94. SEYEDSALEHI A, Warrier V, Bethlehem RAI, Perry BI, et al
    Educational attainment, structural brain reserve and Alzheimer's disease: a Mendelian randomization analysis.
    Brain. 2022 Oct 31. pii: 6780317. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. NEMY M, Dyrba M, Brosseron F, Buerger K, et al
    Cholinergic white matter pathways along the Alzheimer's disease continuum.
    Brain. 2022 Oct 26. pii: 6775152. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. KOCH G, Casula EP, Bonni S, Borghi I, et al
    Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial.
    Brain. 2022 Oct 25. pii: 6701823. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. LECLERC M, Bourassa P, Tremblay C, Caron V, et al
    Cerebrovascular insulin receptors are defective in Alzheimer's disease.
    Brain. 2022 Oct 25. pii: 6761474. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. LI X, Ospitalieri S, Robberechts T, Hofmann L, et al
    Seeding, maturation and propagation of amyloid beta-peptide aggregates in Alzheimer's disease.
    Brain. 2022;145:3558-3570.
    PubMed     Abstract available
    
    
    
99. SINGLETON EH, Fieldhouse JLP, van 't Hooft JJ, Scarioni M, et al
    Social cognition deficits and biometric signatures in the behavioural variant of Alzheimer's disease.
    Brain. 2022 Oct 21. pii: 6765142. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2022
100. SPOTORNO N, Strandberg O, Vis G, Stomrud E, et al
     Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease.
     Brain. 2022 Sep 21. pii: 6710203. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. JANELIDZE S, Bali D, Ashton NJ, Barthelemy NR, et al
     Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
     Brain. 2022 Sep 10. pii: 6695388. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. GROOT C, Smith R, Stomrud E, Binette AP, et al
     Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
     Brain. 2022 Sep 9. pii: 6695020. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. BUCKLEY R
     Sex differences in Alzheimer's disease risk: are immune responses the key?
     Brain. 2022 Sep 2. pii: 6686583. doi: 10.1093.
     PubMed    
     
     
     August 2022
104. RABIN JS, Nichols E, La Joie R, Casaletto KB, et al
     Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline.
     Brain. 2022;145:2823-2833.
     PubMed     Abstract available
     
     
     
105. SNELLMAN A, Lantero-Rodriguez J, Emersic A, Vrillon A, et al
     N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases.
     Brain. 2022;145:2834-2848.
     PubMed     Abstract available
     
     
     
106. RIKU Y, Iwasaki Y, Ishigaki S, Akagi A, et al
     Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
     Brain. 2022;145:2769-2784.
     PubMed     Abstract available
     
     
     
107. SAPKOTA D, Florian C, Doherty BM, White KM, et al
     Aqp4 stop codon readthrough facilitates amyloid-beta clearance from the brain.
     Brain. 2022 Aug 24. pii: 6671408. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. INSEL PS, Young CB, Aisen PS, Johnson KA, et al
     Tau positron emission tomography in preclinical Alzheimer's disease.
     Brain. 2022 Aug 13. pii: 6665667. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. COURSE MM, Gudsnuk K, Keene CD, Bird TD, et al
     Aberrant splicing of PSEN2, but not PSEN1, in individuals with sporadic Alzheimer's disease.
     Brain. 2022 Aug 11. pii: 6660735. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. LUO J, Agboola F, Grant E, Morris JC, et al
     Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan.
     Brain. 2022 Aug 4. pii: 6655799. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2022
111. HUSAIN M
     Molecular pathology and biomarker of progression in Alzheimer's disease.
     Brain. 2022;145:2229-2230.
     PubMed    
     
     
     
112. GROOT C, Holstege H, Ossenkoppele R
     Do genetic factors contribute to sex-specific differences in resilience to amyloid pathology?
     Brain. 2022;145:2239-2241.
     PubMed    
     
     
     
113. CASALETTO KB, Nichols E, Aslanyan V, Simone SM, et al
     Sex-specific effects of microglial activation on Alzheimer's disease proteinopathy in older adults.
     Brain. 2022 Jul 23. pii: 6648895. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. LONG JM, Coble DW, Xiong C, Schindler SE, et al
     Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.
     Brain. 2022 Jul 22. pii: 6648721. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. DEWENTER A, Jacob MA, Cai M, Gesierich B, et al
     Disentangling the effects of Alzheimer's and small vessel disease on white matter fibre tracts.
     Brain. 2022 Jul 21. pii: 6647593. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. BIESSELS GJ
     Alzheimer's disease, cerebrovascular disease and dementia: lump, split or integrate?
     Brain. 2022 Jul 15. pii: 6644842. doi: 10.1093.
     PubMed    
     
     
     
117. WANG Q, Huang X, Su Y, Yin G, et al
     Activation of Wnt/beta-catenin pathway mitigates blood-brain barrier dysfunction in Alzheimer's disease.
     Brain. 2022 Jul 5. pii: 6630034. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2022
118. GRAHAM NSN
     Progress towards predicting neurodegeneration and dementia after traumatic brain injury.
     Brain. 2022;145:1874-1876.
     PubMed    
     
     
     
119. JENKINS LM, Wang L, Rosen H, Weintraub S, et al
     A transdiagnostic review of neuroimaging studies of apathy and disinhibition in dementia.
     Brain. 2022;145:1886-1905.
     PubMed     Abstract available
     
     
     
120. MEHRARAM R, Peraza LR, Murphy NRE, Cromarty RA, et al
     Functional and structural brain network correlates of visual hallucinations in Lewy body dementia.
     Brain. 2022;145:2190-2205.
     PubMed     Abstract available
     
     
     
121. LEVEY AI, Qiu D, Zhao L, Hu WT, et al
     A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
     Brain. 2022;145:1924-1938.
     PubMed     Abstract available
     
     
     
122. TANNER JA, Iaccarino L, Edwards L, Asken BM, et al
     Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
     Brain. 2022 Jun 28. pii: 6619120. doi: 10.1093.
     PubMed     Abstract available
     
     
     
123. KAIVOLA K, Shah Z, Chia R, Scholz SW, et al
     Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups.
     Brain. 2022;145:1757-1762.
     PubMed     Abstract available
     
     
     May 2022
124. TONIOLO S
     What plasma biomarkers tell us about hippocampal microstructural changes in Alzheimer's disease.
     Brain. 2022 May 25. pii: 6591892. doi: 10.1093.
     PubMed    
     
     
     
125. DUZEL E, Ziegler G, Berron D, Maass A, et al
     Amyloid pathology but not APOE epsilon4 status is permissive for tau-related hippocampal dysfunction.
     Brain. 2022;145:1473-1485.
     PubMed     Abstract available
     
     
     
126. KO H, Kim S, Kim K, Jung SH, et al
     Genome-wide association study of occupational attainment as a proxy for cognitive reserve.
     Brain. 2022;145:1436-1448.
     PubMed     Abstract available
     
     
     
127. MORRIS JC, Weiner M, Xiong C, Beckett L, et al
     Autosomal dominant and sporadic late onset Alzheimer disease share a common in vivo pathophysiology.
     Brain. 2022 May 17. pii: 6587090. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. MORRISON MS, Aparicio HJ, Blennow K, Zetterberg H, et al
     Antemortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy.
     Brain. 2022 May 13. pii: 6585495. doi: 10.1093.
     PubMed     Abstract available
     
     
     
129. 
     Correction to: Brain amyloid-beta oligomers in ageing and Alzheimer's disease.
     Brain. 2022 May 13. pii: 6585189. doi: 10.1093.
     PubMed    
     
     
     
130. EISSMAN JM, Dumitrescu L, Mahoney ER, Smith AN, et al
     Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.
     Brain. 2022 May 13. pii: 6585174. doi: 10.1093.
     PubMed     Abstract available
     
     
     
131. ZHU WM, Neuhaus A, Beard DJ, Sutherland BA, et al
     Neurovascular coupling mechanisms in health and neurovascular uncoupling in Alzheimer's disease.
     Brain. 2022 May 13. pii: 6585171. doi: 10.1093.
     PubMed     Abstract available
     
     
     
132. VROMEN EM, de Boer SCM, Teunissen CE, Rozemuller A, et al
     Biomarker A+T-: is this Alzheimer's disease or not? A combined CSF and pathology study.
     Brain. 2022 May 2. pii: 6576655. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2022
133. BARKER MS, Gottesman RT, Manoochehri M, Chapman S, et al
     Proposed research criteria for prodromal behavioural variant frontotemporal dementia.
     Brain. 2022;145:1079-1097.
     PubMed     Abstract available
     
     
     
134. LEGAZ A, Abrevaya S, Dottori M, Gonzalez Campo C, et al
     Multimodal mechanisms of human socially reinforced learning across neurodegenerative diseases.
     Brain. 2022;145:1052-1068.
     PubMed     Abstract available
     
     
     
135. MESULAM MM, Coventry CA, Bigio EH, Sridhar J, et al
     Neuropathological fingerprints of survival, atrophy and language in primary progressive aphasia.
     Brain. 2022 Apr 20. pii: 6570516. doi: 10.1093.
     PubMed     Abstract available
     
     
     
136. SHAHID SS, Wen Q, Risacher SL, Farlow MR, et al
     Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease.
     Brain. 2022 Apr 12. pii: 6566798. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. OLIVEROS G, Wallace CH, Chaudry O, Liu Q, et al
     Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation.
     Brain. 2022 Apr 12. pii: 6566790. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. STEVENSON-HOARE J, Heslegrave A, Leonenko G, Fathalla D, et al
     Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease.
     Brain. 2022 Apr 6. pii: 6564132. doi: 10.1093.
     PubMed     Abstract available
     
     
     
139. PADHI S, Sarangi S, Nayak N, Pati A, et al
     OAS1 rs1131454 genetic variant is associated with Alzheimer's disease: an epidemiological analysis.
     Brain. 2022 Apr 6. pii: 6564066. doi: 10.1093.
     PubMed    
     
     
     March 2022
140. JEONG YY, Han S, Jia N, Zhang M, et al
     Broad activation of the Parkin pathway induces synaptic mitochondrial deficits in early tauopathy.
     Brain. 2022;145:305-323.
     PubMed     Abstract available
     
     
     
141. BENATAR M, Wuu J, McHutchison C, Postuma RB, et al
     Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.
     Brain. 2022;145:27-44.
     PubMed     Abstract available
     
     
     
142. HOSOKAWA M, Masuda-Suzukake M, Shitara H, Shimozawa A, et al
     Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms.
     Brain. 2022;145:349-361.
     PubMed     Abstract available
     
     
     
143. GIACOBINI E, Cuello AC, Fisher A
     Reimagining cholinergic therapy for Alzheimer's disease.
     Brain. 2022 Mar 15. pii: 6548684. doi: 10.1093.
     PubMed     Abstract available
     
     
     
144. SHETTY AK
     Can rapamycin slow down memory decline in Alzheimer's disease with seizures?
     Brain. 2022 Mar 12. pii: 6547363. doi: 10.1093.
     PubMed    
     
     
     
145. LAM AD, Shafi MM
     Towards a coherent view of network hyperexcitability in Alzheimer's disease.
     Brain. 2022 Mar 8. pii: 6544859. doi: 10.1093.
     PubMed    
     
     
     
146. LIN CP, Frigerio I, Boon BDC, Zhou Z, et al
     Structural (dys)connectivity associates with cholinergic cell density in Alzheimer's disease.
     Brain. 2022 Mar 8. pii: 6543231. doi: 10.1093.
     PubMed     Abstract available
     
     
     
147. GABRIELLI M, Prada I, Joshi P, Falcicchia C, et al
     Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer's disease.
     Brain. 2022 Mar 3. pii: 6541881. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2022
148. BEAMAN EE, Bonde AN, Ulv Larsen SM, Ozenne B, et al
     Blood-brain barrier permeable beta-blockers linked to lower risk of Alzheimer's disease in hypertension.
     Brain. 2022 Feb 23. pii: 6535129. doi: 10.1093.
     PubMed     Abstract available
     
     
     
149. PERIS L, Parato J, Qu X, Soleilhac JM, et al
     Tubulin tyrosination regulates synaptic function and is disrupted in Alzheimer's disease.
     Brain. 2022 Feb 11. pii: 6527175. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2022
150. KARANTH SD, Katsumata Y, Nelson PT, Fardo DW, et al
     Cancer diagnosis is associated with a lower burden of dementia and less Alzheimer's-type neuropathology.
     Brain. 2022 Jan 30. pii: 6517521. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. WIESMAN AI, Murman DL, Losh RA, Schantell M, et al
     Spatially resolved neural slowing predicts impairment and amyloid burden in Alzheimer's disease.
     Brain. 2022 Jan 28. pii: 6516524. doi: 10.1093.
     PubMed     Abstract available
     
     
     
152. MARTINO ADAMI PV, Orellana A, Garcia P, Kleineidam L, et al
     Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type.
     Brain. 2022 Jan 28. pii: 6516341. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. STERN AM, Liu L, Jin S, Liu W, et al
     A calcium-sensitive antibody isolates soluble amyloid-beta aggregates and fibrils from Alzheimer's disease brain.
     Brain. 2022 Jan 27. pii: 6516009. doi: 10.1093.
     PubMed     Abstract available
     
     
     
154. ALI M, Falkenhain K, Njiru BN, Murtaza-Ali M, et al
     VEGF signalling causes stalls in brain capillaries and reduces cerebral blood flow in Alzheimer's mice.
     Brain. 2022 Jan 20. pii: 6512043. doi: 10.1093.
     PubMed     Abstract available
     
     
     
155. BRIDEL C, Somers C, Sieben A, Rozemuller A, et al
     Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers.
     Brain. 2022 Jan 13. pii: 6506576. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. COOMANS EM, Tomassen J, Ossenkoppele R, Golla SSV, et al
     Genetically identical twins show comparable tau PET load and spatial distribution.
     Brain. 2022 Jan 12. pii: 6504924. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2021
157. LEE Y, Miller MR, Fernandez MA, Berg EL, et al
     Early lysosome defects precede neurodegeneration with amyloid-beta and tau aggregation in NHE6-null rat brain.
     Brain. 2021 Dec 20. pii: 6470622. doi: 10.1093.
     PubMed     Abstract available
     
     
     
158. RANASINGHE KG, Kudo K, Hinkley L, Beagle A, et al
     Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early onset Alzheimer's disease.
     Brain. 2021 Dec 17. pii: 6469013. doi: 10.1093.
     PubMed     Abstract available
     
     
     
159. XHIMA K, Markham-Coultes K, Kofoed RH, Saragovi HU, et al
     Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies.
     Brain. 2021 Dec 17. pii: 6469023. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. TSAI HH, Chen YF, Yen RF, Lo YL, et al
     Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau.
     Brain. 2021;144:3371-3380.
     PubMed     Abstract available
     
     
     
161. PASCOAL TA, Benedet AL, Tudorascu DL, Therriault J, et al
     Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
     Brain. 2021;144:3517-3528.
     PubMed     Abstract available
     
     
     
162. ABRAHAMSON EE, Kofler JK, Becker CR, Price JC, et al
     11C-PiB PET can underestimate brain amyloid-beta burden when cotton wool plaques are numerous.
     Brain. 2021 Dec 16. pii: 6464340. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2021
163. VERDI S, Marquand AF, Schott JM, Cole JH, et al
     Beyond the average patient: how neuroimaging models can address heterogeneity in dementia.
     Brain. 2021;144:2946-2953.
     PubMed     Abstract available
     
     
     October 2021
164. ZHANG Y, Zhang Y, Aman Y, Ng CT, et al
     Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway.
     Brain. 2021;144:2759-2770.
     PubMed     Abstract available
     
     
     
165. LUCEY BP, Wisch J, Boerwinkle AH, Landsness EC, et al
     Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease.
     Brain. 2021 Oct 20. pii: 6401973. doi: 10.1093.
     PubMed     Abstract available
     
     
     
166. LEVY JP, Bezgin G, Savard M, Pascoal TA, et al
     18F-MK-6240 tau-PET in genetic frontotemporal dementia.
     Brain. 2021 Oct 19. pii: 6402002. doi: 10.1093.
     PubMed     Abstract available
     
     
     
167. MAGUSALI N, Graham AC, Piers TM, Panichnantakul P, et al
     A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene.
     Brain. 2021 Oct 7. pii: 6382473. doi: 10.1093.
     PubMed     Abstract available
     
     
     
168. KHAN AF, Adewale Q, Baumeister TR, Carbonell F, et al
     Personalized brain models identify neurotransmitter receptor changes in Alzheimer's disease.
     Brain. 2021 Oct 4. pii: 6380944. doi: 10.1093.
     PubMed     Abstract available
     
     
     
169. SCHUMACHER J, Ray NJ, Hamilton CA, Donaghy PC, et al
     Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer's disease.
     Brain. 2021 Oct 4. pii: 6380941. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2021
170. 
     Erratum to: Cardiovascular brain impulses in Alzheimer's disease.
     Brain. 2021 Sep 22. pii: 6373794. doi: 10.1093.
     PubMed    
     
     
     
171. STOTHART G, Smith LJ, Milton A, Coulthard E, et al
     A passive and objective measure of recognition memory in Alzheimer's disease using Fastball memory assessment.
     Brain. 2021 Sep 20. pii: 6372384. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2021
172. KHAN AR, Ottoy J, Goubran M
     Towards a comprehensive 3D mapping of tau progression in early Alzheimer's disease.
     Brain. 2021 Aug 23. pii: 6356553. doi: 10.1093.
     PubMed    
     
     
     
173. DAVILA-BOUZIGUET E, Casoliba-Melich A, Targa-Fabra G, Galera-Lopez L, et al
     Functional protection in J20/VLW mice: a model of non-demented with Alzheimer's disease neuropathology.
     Brain. 2021 Aug 23. pii: 6356505. doi: 10.1093.
     PubMed     Abstract available
     
     
     
174. BOYLE PA, Wang T, Yu L, Wilson RS, et al
     To what degree is late life cognitive decline driven by age-related neuropathologies?
     Brain. 2021;144:2166-2175.
     PubMed     Abstract available
     
     
     
175. HOLLAND N, Malpetti M, Rittman T, Mak EE, et al
     Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study.
     Brain. 2021 Aug 16. pii: 6353021. doi: 10.1093.
     PubMed     Abstract available
     
     
     
176. STROM A, Iaccarino L, Edwards L, Lesman-Segev OH, et al
     Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
     Brain. 2021 Aug 9. pii: 6346980. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2021
177. PAUMIER A, Boisseau S, Jacquier-Sarlin M, Pernet-Gallay K, et al
     Astrocyte-neuron interplay is critical for Alzheimer's disease pathogenesis and is rescued by TRPA1 channel blockade.
     Brain. 2021 Jul 24. pii: 6327685. doi: 10.1093.
     PubMed     Abstract available
     
     
     
178. GOURMAUD S, Stewart DA, Irwin DJ, Roberts N, et al
     The role of mTORC1 activation in seizure-induced exacerbation of Alzheimer's disease.
     Brain. 2021 Jul 15. pii: 6321945. doi: 10.1093.
     PubMed     Abstract available
     
     
     
179. BERRON D, van Westen D, Ossenkoppele R, Strandberg O, et al
     Corrigendum to: Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease.
     Brain. 2021 Jul 14. pii: 6321152. doi: 10.1093.
     PubMed    
     
     
     
180. PEREIRA JB, Janelidze S, Smith R, Mattsson-Carlgren N, et al
     Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer's disease.
     Brain. 2021 Jul 14. pii: 6321226. doi: 10.1093.
     PubMed     Abstract available
     
     
     
181. BAILES SM, Lewis LD
     Distinct cardiac-locked brain pulsations in Alzheimer's disease.
     Brain. 2021 Jul 9. pii: 6318392. doi: 10.1093.
     PubMed    
     
     
     
182. HORIE K, Barthelemy NR, Sato C, Bateman RJ, et al
     Corrigendum to: CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.
     Brain. 2021 Jul 3. pii: 6313379. doi: 10.1093.
     PubMed    
     
     
     June 2021
183. RIES M, Watts H, Mota BC, Lopez MY, et al
     Annexin A1 restores cerebrovascular integrity concomitant with reduced amyloid-beta and tau pathology.
     Brain. 2021;144:1526-1541.
     PubMed     Abstract available
     
     
     
184. MATTHEWS DC, Mao X, Dowd K, Tsakanikas D, et al
     Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease.
     Brain. 2021 Jun 18. pii: 6305835. doi: 10.1093.
     PubMed     Abstract available
     
     
     
185. PATEL AG, Nehete PN, Krivoshik SR, Pei X, et al
     Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys.
     Brain. 2021 Jun 15. pii: 6297373. doi: 10.1093.
     PubMed     Abstract available
     
     
     
186. SCHUMACHER J, Gunter JL, Przybelski SA, Jones DT, et al
     Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks.
     Brain. 2021 Jun 11. pii: 6296589. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2021
187. 
     Erratum to: The development and convergence of co-pathologies in Alzheimer's disease.
     Brain. 2021 May 23. pii: 6282423. doi: 10.1093.
     PubMed    
     
     
     
188. DEHGHANI N, Bras J, Guerreiro R
     Erratum to: How understudied populations have contributed to our understanding of Alzheimer's disease genetics.
     Brain. 2021 May 20. pii: 6279241. doi: 10.1093.
     PubMed    
     
     
     April 2021
189. O'CONNOR A, Pannee J, Poole T, Arber C, et al
     Plasma amyloid-beta ratios in autosomal dominant Alzheimer's disease: the influence of genotype.
     Brain. 2021 Apr 23. pii: 6248083. doi: 10.1093.
     PubMed     Abstract available
     
     
     
190. DEHGHANI N, Bras J, Guerreiro R
     How understudied populations have contributed to our understanding of Alzheimer's disease genetics.
     Brain. 2021 Apr 23. pii: 6247156. doi: 10.1093.
     PubMed     Abstract available
     
     
     
191. YAO Y, Kang SS, Xia Y, Wang ZH, et al
     A delta-secretase-truncated APP fragment activates CEBPB, mediating Alzheimer's disease pathologies.
     Brain. 2021 Apr 20. pii: 6242262. doi: 10.1093.
     PubMed     Abstract available
     
     
     
192. 
     Erratum to: Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
     Brain. 2021 Apr 20. pii: 6238673. doi: 10.1093.
     PubMed    
     
     
     
193. OZAWA S, Hori Y, Shimizu Y, Taniguchi A, et al
     Photo-oxygenation by a biocompatible catalyst reduces amyloid-beta levels in Alzheimer's disease mice.
     Brain. 2021 Apr 14. pii: 6224831. doi: 10.1093.
     PubMed     Abstract available
     
     
     
194. TOME SO, Thal DR
     Co-pathologies in Alzheimer's disease: just multiple pathologies or partners in crime?
     Brain. 2021;144:706-708.
     PubMed    
     
     
     
195. 
     Corrigendum to: Monitoring the progression of Alzheimer's disease with tau-PET.
     Brain. 2021 Apr 6. pii: 6213355. doi: 10.1093.
     PubMed    
     
     
     March 2021
196. RAJNA Z, Mattila H, Huotari N, Tuovinen T, et al
     Cardiovascular brain impulses in Alzheimer's disease.
     Brain. 2021 Mar 31. pii: 6206368. doi: 10.1093.
     PubMed     Abstract available
     
     
     
197. YAP SY, Frias B, Wren MC, Scholl M, et al
     Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease.
     Brain. 2021 Mar 20. pii: 6179104. doi: 10.1093.
     PubMed     Abstract available
     
     
     
198. EWERS M, Luan Y, Frontzkowski L, Neitzel J, et al
     Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease.
     Brain. 2021 Mar 16. pii: 6174116. doi: 10.1093.
     PubMed     Abstract available
     
     
     
199. ASBY D, Boche D, Allan S, Love S, et al
     Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer's disease.
     Brain. 2021 Mar 16. pii: 6173392. doi: 10.1093.
     PubMed     Abstract available
     
     
     
200. SPINA S, La Joie R, Petersen C, Nolan AL, et al
     Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease.
     Brain. 2021 Mar 9. pii: 6164966. doi: 10.1093.
     PubMed     Abstract available
     
     
     
201. HUSAIN M
     Blood tests to screen for Alzheimer's disease.
     Brain. 2021;144:355-356.
     PubMed    
     
     
     
202. KIM JH, Afridi R, Han J, Jung HG, et al
     Gamma subunit of complement component 8 is a neuroinflammation inhibitor.
     Brain. 2021;144:528-552.
     PubMed     Abstract available
     
     
     February 2021
203. JAGUST W
     Integrating events in the disintegration of Alzheimer's disease.
     Brain. 2021;144:11-14.
     PubMed    
     
     
     
204. TIJMS BM, Teunissen CE
     Concatenating plasma p-tau to Alzheimer's disease.
     Brain. 2021;144:14-17.
     PubMed    
     
     
     January 2021
205. KESHAVAN A, Pannee J, Karikari TK, Rodriguez JL, et al
     Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70.
     Brain. 2021 Jan 22. pii: 6105867. doi: 10.1093.
     PubMed     Abstract available
     
     
     
206. 
     Erratum to: Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons.
     Brain. 2021 Jan 12. pii: 6091150. doi: 10.1093.
     PubMed    
     
     
     December 2020
207. JOHNSON JCS, Marshall CR, Weil RS, Bamiou DE, et al
     Hearing and dementia: from ears to brain.
     Brain. 2020 Dec 22. pii: 6044086. doi: 10.1093.
     PubMed     Abstract available
     
     
     
208. MONTERO-CRESPO M, Dominguez-Alvaro M, Alonso-Nanclares L, DeFelipe J, et al
     Three-dimensional analysis of synaptic organization in the hippocampal CA1 field in Alzheimer's disease.
     Brain. 2020 Dec 16. pii: 6038920. doi: 10.1093.
     PubMed     Abstract available
     
     
     
209. HORIE K, Barthelemy NR, Sato C, Bateman RJ, et al
     CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.
     Brain. 2020 Dec 7. pii: 6024973. doi: 10.1093.
     PubMed     Abstract available
     
     
     
210. TEUNISSEN CE, Thijssen EH, Verberk IMW
     Plasma p-tau217: from 'new kid' to most promising candidate for Alzheimer's disease blood test.
     Brain. 2020;143:3170-3172.
     PubMed    
     
     
     
211. PEREIRA JB, Janelidze S, Ossenkoppele R, Kvartsberg H, et al
     Untangling the association of amyloid-beta and tau with synaptic and axonal loss in Alzheimer's disease.
     Brain. 2020 Dec 5. pii: 6024803. doi: 10.1093.
     PubMed     Abstract available
     
     
     
212. TIJMS BM, Gobom J, Reus L, Jansen I, et al
     Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics.
     Brain. 2020;143:3776-3792.
     PubMed     Abstract available
     
     
     
213. SMITH R, Strandberg O, Mattsson-Carlgren N, Leuzy A, et al
     The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
     Brain. 2020;143:3805-3815.
     PubMed     Abstract available
     
     
     
214. FLORES-AGUILAR L, Iulita MF, Kovecses O, Torres MD, et al
     Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.
     Brain. 2020;143:3653-3671.
     PubMed     Abstract available
     
     
     November 2020
215. MOSCOSO A, Grothe MJ, Ashton NJ, Karikari TK, et al
     Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
     Brain. 2020 Nov 30. pii: 6012955. doi: 10.1093.
     PubMed     Abstract available
     
     
     
216. BRIER MR, Day GS
     Serum neurofilament light chain uncovers neurodegeneration early in the course of Alzheimer's disease.
     Brain. 2020 Nov 30. pii: 6012788. doi: 10.1093.
     PubMed    
     
     
     
217. SUR C, Kost J, Scott D, Adamczuk K, et al
     BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
     Brain. 2020 Nov 30. pii: 6012787. doi: 10.1093.
     PubMed     Abstract available
     
     
     
218. RUAN Z, Pathak D, Venkatesan Kalavai S, Yoshii-Kitahara A, et al
     Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons.
     Brain. 2020 Nov 27. pii: 6007752. doi: 10.1093.
     PubMed     Abstract available
     
     
     
219. BENEDET AL, Leuzy A, Pascoal TA, Ashton NJ, et al
     Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
     Brain. 2020 Nov 19. pii: 5990278. doi: 10.1093.
     PubMed     Abstract available
     
     
     
220. JIA L, Li F, Wei C, Zhu M, et al
     Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study.
     Brain. 2020 Nov 14. pii: 5981992. doi: 10.1093.
     PubMed     Abstract available
     
     
     
221. LIU KY, Reeves S, McAleese KE, Attems J, et al
     Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer's disease.
     Brain. 2020 Nov 14. pii: 5981742. doi: 10.1093.
     PubMed     Abstract available
     
     
     
222. JI X, Liu G
     rs34331204 regulates TSPAN13 expression and contributes to Alzheimer's disease with sex differences.
     Brain. 2020 Nov 11. pii: 5974904. doi: 10.1093.
     PubMed    
     
     
     
223. DUMITRESCU L, Hohman TJ
     Reply: rs34331204 regulates TSPAN13 expression and contributes to Alzheimer's disease with sex differences.
     Brain. 2020 Nov 11. pii: 5974883. doi: 10.1093.
     PubMed    
     
     
     
224. JOSEPHS KA, Martin PR, Weigand SD, Tosakulwong N, et al
     Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy.
     Brain. 2020 Nov 5. pii: 5956321. doi: 10.1093.
     PubMed     Abstract available
     
     
     
225. SOLEIMANI-MEIGOONI DN, Iaccarino L, La Joie R, Baker S, et al
     18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
     Brain. 2020 Nov 3. pii: 5952719. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2020
226. MATTSSON-CARLGREN N, Janelidze S, Palmqvist S, Cullen N, et al
     Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.
     Brain. 2020 Oct 17. pii: 5929275. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2020
227. HARDY CJD, Yong KXX, Goll JC, Crutch SJ, et al
     Impairments of auditory scene analysis in posterior cortical atrophy.
     Brain. 2020 Sep 1. pii: 5900355. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2020
228. PASCOAL TA, Therriault J, Benedet AL, Savard M, et al
     18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
     Brain. 2020 Jul 16. pii: 5872095. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2020
229. PRZYBYLA M, van Eersel J, van Hummel A, van der Hoven J, et al
     Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature.
     Brain. 2020;143:1889-1904.
     PubMed     Abstract available
     
     
     January 2020
230. ROBINSON JL, Richardson H, Xie SX, Suh E, et al
     The development and convergence of co-pathologies in Alzheimer's disease.
     Brain. 2020 Jan 15. pii: 6101614. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.